4.5 Article

A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 85, Issue 4, Pages 1745-1754

Publisher

IOS PRESS
DOI: 10.3233/JAD-215163

Keywords

Alzheimer's disease; cognitive function genetic risk scores; pathway; tau

Categories

Funding

  1. National Natural Science Foundation of China [81771451, 81871438]
  2. Beijing Natural Science Funds for Distinguished Young Scholar [JQ20036]
  3. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01AG024904]
  4. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  5. National Institute on Aging
  6. National Institute of Biomedical Imaging and Bioengineering
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. Biogen
  11. CereSpir, Inc.
  12. Cogstate
  13. Elan Pharmaceuticals, Inc.
  14. Eli Lilly and Company
  15. EuroImmun
  16. F. Hoffmann-La Roche Ltd,
  17. Genentech, Inc.
  18. Fujirebio
  19. GE Healthcare
  20. IXICO Ltd.
  21. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  22. Johnson & Johnson Pharmaceutical Research & Development LLC.
  23. Lumosity
  24. Lundbeck
  25. Merck Co., Inc.
  26. Meso Scale Diagnostics, LLC.
  27. NeuroRx Research
  28. Neurotrack Technologies
  29. Novartis Pharmaceuticals Corporation
  30. Pfizer Inc.
  31. Piramal Imaging
  32. Servier
  33. Takeda Pharmaceutical Company
  34. Transition Therapeutics
  35. Canadian Institutes of Health Research
  36. AbbVie
  37. Bristol-Myers Squibb Company
  38. Eisai Inc.

Ask authors/readers for more resources

This study explored the potential of using specific polygenic risk scores (PRSs) as predictors of tau pathology and cognitive decline in non-demented individuals. The results showed that higher PRS was associated with elevated tau levels, greater rates of tau level changes, and memory impairment mediated by increased tau levels.
Background: Tauopathy is a primary neuropathological hallmark of Alzheimer's disease with a strong relationship to cognitive impairment. In the brain, tau aggregation is associated with the regulation of tau kinases and the binding ability of tau to microtubules. Objective: To explore the potential for using specific polygenic risk scores (PRSs), combining the genetic influences involved in tau-protein kinases and the tau-protein binding pathway, as predictors of tau pathology and cognitive decline in non-demented individuals. Methods: We computed a pathway-specific PRS using summary statistics from previous large-scale genome-wide association studies of dementia. We examined whether PRS is related to tau uptake in positron emission tomography (PET), tau levels, and the rate of tau level changes in cerebrospinal fluid (CSF). We further assessed whether PRS is associated with memory impairment mediated by CSF tau levels. Results: A higher PRS was related to elevated CSF tau levels and tau-PET uptake at baseline, as well as greater rates of change in CSF tau levels. Moreover, PRS was associated with memory impairment, mediated by increased CSF tau levels. The association between PRS and tau pathology was significant when APOE was excluded, even among females. However, the effect of PRS on cognitive decline appeared to be driven by the inclusion of APOE. Conclusion: The influence of genetic risk in a specific tau-related biological pathway may make an individual more susceptible to tau pathology, resulting in cognitive dysfunction in an early preclinical phase of the disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available